Clinical Trial Update: CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating CD19/CD22 bicistronic CAR T cells in children and young adults with recurrent or refractory CD19/CD22-expressing B-cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CD19/CD22 bicistronic CAR T cells

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B-NHL, B-Non Hodgkin Lymphoma | Phase 1, Phase 2 | Status: RECRUITING